High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: Results from the SEARCH database

International Braz J Urol

Volumn 39, Issue 3, 2013, Pages 312-318

  Moreira, Daniel M ^a   Bañez, Lionel L ^a   Presti Jr , Joseph C ^c,d,e   Aronson, William J ^e,f   Terris, Martha K ^e,g   Kane, Christopher J ^g   Amling, Christopher L ^h,i   Freedland, Stephen J ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g UCSD MEDICAL CENTER   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Disease free survival; Prostate specific antigen; Prostatectomy; Prostatic Neoplasms

Indexed keywords

FOLIC ACID; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; AGED; ARTICLE; BLOOD; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

AGE FACTORS; AGED; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84881512320     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2013.03.03     Document Type: Article

References (19)

1. Kim YI: Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2220-5.
2. Choi SW, Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr. 2000; 130: 129-32.
3. Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW: Serum levels of folate, lycopene, ß-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr. 2010; 64: 1235-8.
4. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, et al.: Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009; 101: 432-5.
5. Bañez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL, et al.: The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis. 2010; 13: 173-7.
6. Giovannucci E, Chan AT: Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol. 2010; 28: 4081-5.
7. Wei EK, Wolin KY, Colditz GA: Time course of risk factors in cancer etiology and progression. J Clin Oncol. 2010; 28: 4052-7.
8. Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P: Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer. 2005; 113: 819-24.
9. Pelucchi C, Galeone C, Talamini R, Negri E, Parpinel M, Franceschi S, et al.: Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol Biomarkers Prev. 2005; 14: 944-8.
10. Stevens VL, Rodriguez C, Pavluck AL, McCullough ML, Thun MJ, Calle EE: Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol. 2006; 163: 989-96.
11. Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, Egevad L, et al.: Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev. 2008; 17: 279-85.
12. Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al.: Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1632-42.
13. Dietrich M, Brown CJ, Block G: The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr. 2005; 24: 266-74.
14. Hubner RA, Houlston RS: Folate and colorectal cancer prevention. Br J Cancer. 2009; 100: 233-9.
15. BistulfiG, Vandette E, Matsui S, Smiraglia DJ: Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol.
16. Basten GP, Duthie SJ, Pirie L, Vaughan N, Hill MH, Powers HJ: Sensitivity of markers of DNA stability and DNA repair activity to folate supplementation in healthy volunteers. Br J Cancer. 2006; 94: 1942-7.
17. Wei Q, Shen H, Wang LE, Duphorne CM, Pillow PC, Guo Z, et al.: Association between low dietary folate intake and suboptimal cellular DNA repair capacity. Cancer Epidemiol Biomarkers Prev. 2003; 12: 963-9.
18. Choi SW, Mason JB: Folate status: effects on pathways of colorectal carcinogenesis. J Nutr. 2002; 132: 2413S-2418S.
19. Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R, Pietinen P, Barrett MJ, Taylor PR, et al.: Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev 2003; 12: 1271-2.